Who We Are
Leadership
Sumit Aggarwal
President and Chief Executive Officer
Mr. Sumit Aggarwal joined Eloxx as our President and Chief Executive Officer on April 1, 2021, and previously served as President and Chief Executive Officer and a director of Zikani since 2019. Mr. Aggarwal joined Zikani in 2018 as Chief Financial Officer and Chief Business Officer, and led the transformation of Zikani from an early stage technology company to a rare disease and oncology-focused organization. ...see morePrior to joining Zikani, from 2015 to 2018, Mr. Aggarwal served as acting President and Chief Financial Officer of Progenity, Inc., a private genetic services company offering pre-natal genetic testing to OB/GYN practices. From 2016 to 2018, Mr. Aggarwal served as a member of the board of directors of NEOSEQ, a privately-held genetic sequencing based diagnostic company. Mr. Aggarwal has also held leadership roles in healthcare and biotechnology at Adage Capital and as an Associate Partner at McKinsey & Company in its healthcare practice.
Mr. Aggarwal has more than 20 years of experience in pharmaceutical and biotechnology commercial operations, investment management, management consulting, and has been successful in transforming companies by reinvigorating innovation, growth and profitability, and raising capital for promising technology companies. Mr. Aggarwal holds an M.B.A. with distinction from the Johnson School, Cornell University, and a Bachelor of Technology with Honors in Chemical Engineering from the Indian Institute of Technology, Kharagpur.
...see less
Mr. Aggarwal has more than 20 years of experience in pharmaceutical and biotechnology commercial operations, investment management, management consulting, and has been successful in transforming companies by reinvigorating innovation, growth and profitability, and raising capital for promising technology companies. Mr. Aggarwal holds an M.B.A. with distinction from the Johnson School, Cornell University, and a Bachelor of Technology with Honors in Chemical Engineering from the Indian Institute of Technology, Kharagpur.
...see less
Vijay Modur
Head of Research and Development
Dr. Vijay Modur became our Head of Research and Development on April 1, 2021, and previously served as the Head of R&D, Chief Scientific and Medical Officer of Zikani Therapeutics, Inc. In his more than 20 years in pharmaceutical and diagnostic roles in R&D, Dr. Modur has successfully translated research discovery efforts into products that impacted medical practice. ...see morePrior to joining Zikani, Dr. Modur led the venglustat rare disease program at Sanofi across multiple rare disease indications into phase 2 and phase 3 clinical development as well as other early development programs. Prior to Sanofi, Dr. Modur held leadership roles at HTG Molecular, Novartis Oncology and Merck Research Labs. Dr. Modur obtained his M.B.B.S. from Karnatak University and his Ph.D. from University of Utah. Dr. Modur was a resident in Clinical Pathology at Washington University School of Medicine where he also completed his post-doctoral fellowship.
...see less
...see less
Daniel Geffken
Interim Chief Financial Officer
Mr. Daniel Geffken was appointed as Interim Chief Financial Officer on April 1, 2021. Mr. Geffken is a founder of Danforth Advisors and brings more than 30 years of financial experience to his work for Danforth clients, ranging from start-ups to publicly traded companies with over a billion dollars in market capitalization. ...see moreHe has served as chief financial officer and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, GenePeeks, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Since 2013, Mr. Geffken has participated in eleven initial public offerings. Over the course of his career, he has helped life sciences companies raise more than two billion dollars in equity and debt securities. Mr. Geffken holds a B.S. from The Wharton School, University of Pennsylvania, and an M.B.A. from Harvard Business School.
...see less
...see less
Ali Hariri
Chief Medical Officer
Ali Hariri, M.D., is Eloxx’s Chief Medical Officer, responsible for overseeing clinical development efforts for the company’s promising pipeline of therapies to treat rare diseases. Prior to joining Eloxx, Dr. Hariri served as Senior Global Project Head in Rare Disease Clinical Development at Sanofi-Genzyme where he oversaw key functions responsible for advancing a number of investigational therapies along with approval of supplemental indications for on-market therapies....see more
Prior to his role as Global Project Head at Sanofi-Genzyme, Dr. Hariri held several positions of increasing responsibility with expertise across a range of therapeutic areas including renal and immunology. Before joining Sanofi, Dr. Hariri held clinical development and medical affairs roles at Ionis and Takeda coordinating publication planning and health economics research. Dr. Hariri was also a practicing nephrologist.
Dr. Hariri earned his M.D. from the University of California San Diego School of Medicine, and his Bachelor of Science degree in biochemistry from California State University. He completed his residency at Case Western Reserve and a fellowship at Yale University School of Medicine. He served as faculty in the section of nephrology at Yale.
...see less
Prior to his role as Global Project Head at Sanofi-Genzyme, Dr. Hariri held several positions of increasing responsibility with expertise across a range of therapeutic areas including renal and immunology. Before joining Sanofi, Dr. Hariri held clinical development and medical affairs roles at Ionis and Takeda coordinating publication planning and health economics research. Dr. Hariri was also a practicing nephrologist.
Dr. Hariri earned his M.D. from the University of California San Diego School of Medicine, and his Bachelor of Science degree in biochemistry from California State University. He completed his residency at Case Western Reserve and a fellowship at Yale University School of Medicine. He served as faculty in the section of nephrology at Yale.
...see less
